Allogene Therapeutics is advancing cema-cel, a CAR T therapy targeting earlier intervention in high-risk large B-cell lymphoma (LBCL). Interim ALPHA3 trial data revealed 58.3% minimal residual disease (MRD) negativity for cema-cel versus 16.7% in observation, highlighting its potential effectiveness and a favorable safety profile suitable for outpatient use. Despite a recent stock rally, the market undervalues Allogene's platform, with an enterprise value under $500 million. The analyst maintains a long-term buy rating, anticipating future event-free survival (EFS) results to confirm cema-cel's best-in-class potential, though short-term volatility is expected.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
